At the heart of this pathway, a protein called BRAF acts as a molecular switch that must be rigorously controlled. Frequently affected by so-called oncogenic mutations, BRAF is implicated in several ...
A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group Knowledge on how molecular ...
A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Mitogen-activating protein kinase ...
New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF ...
Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...
In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results